Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 2:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 844 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Attention Deficit and Disruptive Behavior Disorders Clear all
Completed Phase 4 Interventional Results available

Electrophysiological Effects of Guanfacine Extended Release in Attention Deficit Hyperactivity Disorder (ADHD)

NCT01069523
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Guanfacine Extended Release, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
6 Years to 12 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 3, 2026, 2:09 PM EDT
Completed Phase 4 Interventional Results available

Crossover Study to Evaluate the Efficacy of AR11 in Pediatric Patients With ADHD in a Laboratory Classroom Setting

NCT01986062
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
AR11, Placebo
Drug
Lead sponsor
Arbor Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 12 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
7
States / cities
Bradenton, Florida • Maitland, Florida • South Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Oct 3, 2026, 2:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparative Effectiveness Research for Two Medical Home Models for Attention Deficit Hyperactivity Disorder

NCT01275378
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
Collaborative Care Plus, Traditional Collaborative Care
Behavioral
Lead sponsor
Boston Medical Center
Other
Eligibility
6 Years to 12 Years
Enrollment
156 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 10, 2016 · Synced Oct 3, 2026, 2:09 PM EDT
Not listed Not applicable Interventional

Randomized Controlled Trial of a Behavioral Training App

NCT06447909
View directory record Official record
Conditions
Behavior, Child, Disruptive Behavior, Executive Dysfunction, Attention-deficit, Anxiety, Depression, Stress
Interventions
Treatment App, Sham app
Behavioral
Lead sponsor
New York University
Other
Eligibility
6 Years to 12 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 7, 2024 · Synced Oct 3, 2026, 2:09 PM EDT
Completed Not applicable Interventional Results available

Continuous Positive Airway Pressure (CPAP) After Adenotonsillectomy in Children

NCT01554527
View directory record Official record
Conditions
Sleep Apnea, Obstructive, Sleep Apnea Syndromes, Child Behavior Disorders, Attention Deficit Disorder With Hyperactivity, Disorders of Excessive Somnolence
Interventions
CPAP treatment, No CPAP treatment
Procedure · Other
Lead sponsor
University of Michigan
Other
Eligibility
5 Years to 12 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Oct 3, 2026, 2:09 PM EDT
Completed Phase 2 Interventional

Atomoxetine for Treating Marijuana-Abusing Adolescents Who Have Attention Deficit Hyperactivity Disorder

NCT00142961
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Marijuana Abuse
Interventions
Atomoxetine, placebo
Drug · Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
14 Years to 21 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 3, 2026, 2:09 PM EDT
Recruiting Not applicable Interventional

Central Executive Training and Parent Training for ADHD

NCT05492422
View directory record Official record
Conditions
ADHD
Interventions
Central Executive Training (CET), Behavioral Parent Training (BPT)
Device · Behavioral
Lead sponsor
Florida State University
Other
Eligibility
8 Years to 12 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 3, 2026, 2:09 PM EDT
Completed Not applicable Interventional Results available

Mobile Behavioral Parent Training for Childhood ADHD: A Micro-randomized Trial

NCT06012851
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Mobile behavioral parent training (mBPT), In the moment feedback, In the moment suggestions
Behavioral
Lead sponsor
Florida International University
Other
Eligibility
7 Years to 12 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 3, 2026, 2:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Behavioral Health Care for Children With ADHD

NCT02972086
View directory record Official record
Conditions
ADHD
Interventions
Behavioral Parent Training (BPT)
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 3, 2026, 2:09 PM EDT
Completed Phase 2 Interventional Results available

Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder

NCT01074294
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
OPDC-34712, Placebo, Stimulant Therapy
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
35
States / cities
Little Rock, Arkansas • Beverly Hills, California • Irvine, California + 32 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Oct 3, 2026, 2:09 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD

NCT03834766
View directory record Official record
Conditions
ADHD
Interventions
AMPH ER Tab 5, 10, 15 and 20 mg, AMPH ER Tab Matching Placebo 5, 10, 15 and 20 mg
Drug
Lead sponsor
Tris Pharma, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
3
States / cities
Bradenton, Florida • Maitland, Florida • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 3, 2026, 2:09 PM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, Diagnosed With Attention-deficit/Hyperactivity Disorder

NCT02466386
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
SPD489
Drug
Lead sponsor
Shire
Industry
Eligibility
4 Years to 5 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
50
States / cities
Dothan, Alabama • Little Rock, Arkansas • Imperial, California + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 3, 2026, 2:09 PM EDT
Completed Phase 2 Interventional Results available

PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without mGluR Mutations

NCT03609619
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
AEVI-001, Placebo
Drug
Lead sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Industry
Eligibility
6 Years to 17 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Wayne, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2021 · Synced Oct 3, 2026, 2:09 PM EDT
Completed Phase 2 Interventional

A Study of Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) in Children With ADHD

NCT02884544
View directory record Official record
Conditions
Attention-Deficit Hyperactivity Disorder (ADHD)
Interventions
HLD100
Drug
Lead sponsor
Ironshore Pharmaceuticals and Development, Inc
Other
Eligibility
6 Years to 12 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Oct 3, 2026, 2:09 PM EDT
Completed Not applicable Interventional

Settling Down for Sleep in ADHD: The Impact of Sensory and Arousal Systems on Sleep in ADHD

NCT06406309
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Sleep Disturbance
Interventions
Power Down manipulation
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
6 Years to 13 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 3, 2026, 2:09 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Methylphenidate and Response to Alcohol Cues Pilot Study

NCT06063200
View directory record Official record
Conditions
Alcohol Use Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate Pill
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 25 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 3, 2026, 2:09 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Effects of Atypical Antipsychotics on Brain Function in Children and Teens With Conduct Disorders

NCT01867398
View directory record Official record
Conditions
Conduct Disorder, fMRI
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
10 Years to 18 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 3, 2026, 2:09 PM EDT
Terminated Phase 2 Interventional Results available

Treatment of Children With ADHD Who do Not Fully Respond to Stimulants

NCT00279409
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
aripiprazole, Sugar pill
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
6 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 19, 2020 · Synced Oct 3, 2026, 2:09 PM EDT
Completed Phase 3 Interventional Results available

Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl

NCT01081132
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
Extended-release Guanfacine Hydrochloride, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
13 Years to 17 Years
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
54
States / cities
Dothan, Alabama • Little Rock, Arkansas • Rolling Hills Estates, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Oct 3, 2026, 2:09 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Brain Activity Flow Patterns Analysis Using Evoked Response Potentials in Youth With ADHD, Bipolar Disorder, or Autism Spectrum Disorders: A Preliminary Study

NCT01506232
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Autism Spectrum Disorder, Bipolar Disorder
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 28, 2024 · Synced Oct 3, 2026, 2:09 PM EDT
Active, not recruiting No phase listed Observational

EndeavorOTC™ Prospective Product Registry

NCT06109051
View directory record Official record
Conditions
ADHD
Interventions
EndeavorOTC
Device
Lead sponsor
Akili Interactive Labs, Inc.
Industry
Eligibility
Not listed
Enrollment
198 participants
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Oct 3, 2026, 2:09 PM EDT
Completed Phase 2 Interventional

Mazindol Controlled Release in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

NCT02808104
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
mazindol
Drug
Lead sponsor
NLS Pharmaceutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Newport Beach, California • Jacksonville, Florida • Marshfield, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Oct 3, 2026, 2:09 PM EDT
Completed Phase 1 Interventional Results available

Lisdexamfetamine Dimesylate (LDX) Pilot Cognition Study to Evaluate the Utility of a Standardized Battery of Tests in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

NCT01010750
View directory record Official record
Conditions
Attention-Deficit Hyperactivity Disorder
Interventions
Lisdexamfetamine Dimesylate (LDX), Immediate Release Mixed Amphetamine Salts (MAS-IR), LDX Placebo + MAS-IR Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 3, 2026, 2:09 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD

NCT02777931
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
NFC-1, Placebo
Drug
Lead sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Industry
Eligibility
12 Years to 17 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced Oct 3, 2026, 2:09 PM EDT